fujirebio - Search News

Order byBest matchMost fresh

News

Alzheimer's, Fujirebio and FDA

Fujirebio Alzheimer’s test wins first FDA clearance

Fujirebio Diagnostics Inc.’s Alzheimer’s disease assay received the U.S. FDA’s first clearance for a blood test for the debilitating neurodegenerative disease. Fujirebio’s Lumipulse G pTau217/ß-Amyloid 1-42 plasma ratio is indicated for the early detection of amyloid plaques associated with Alzheimer’s disease in symptomatic individuals aged 55 years and older.

Continue reading

Medical Device Network on MSN · 14h

FDA grants 510(k) clearance to Fujirebio’s blood-based test for Alzheimer’s

Best Life on MSN · 6h

FDA Approves First-Ever Alzheimer's Blood Test—Here's Who Will Benefit

2d

FDA clears first blood test to diagnose Alzheimer’s disease

U.S. regulators have approved the first blood test to help diagnose Alzheimer’s disease, potentially making it easier to find ...

MyChesCo on MSN2d

Fujirebio and AriBio Achieve Milestone in Biomarker Advancement for Alzheimer’s Disease

Fujirebio Holdings Inc., its subsidiary Fujirebio Diagnostics, Inc., and AriBio Co., Ltd. have announced the successful ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results